Results 51 to 60 of about 37,073 (243)

Ocular manifestations of COVID-19 infection: A review of available information

Kerala Journal of Ophthalmology, 2021
Ocular signs and symptoms have been reported in COVID-19 patients, and there is increasing recognition of conjunctivitis as a prodromal symptom of this disease. There is also a surge of information about corneal, uveal, retinal, and neuroophthalmological
Kaberi Biswas Feroze
doaj   +1 more source

THE BACTERIOLOGY OF CONJUNCTIVITIS [PDF]

The American Journal of the Medical Sciences, 1906
n ...
openaire   +2 more sources

Long‐Term Real‐World Effectiveness of Rupatadine in Chronic Urticaria: A Retrospective Observational Study

JEADV Clinical Practice, EarlyView.
This retrospective observational study analyzed a cohort of chronic urticaria (CU) patients to provide insight into the clinical practice of CU with second‐generation antihistamines (SgAHs) and to evaluate the long‐term real‐world effectiveness of rupatadine in CU. Patients with chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU)
A. M. Giménez‐Arnau, C. Romero, M. March, A. Tomas, I. Izquierdo, R. M. Pujol   +5 more
wiley   +1 more source

Allergic Conjunctivitis

South African Family Practice, 2017
Allergic conjunctivitis is a condition characterized by conjunctival inflammation caused by airborne allergens. The symptoms include: itching, excessive lacrimation, discharge, and conjunctival hyperaemia pink eye).
Muhammed Vally, M O E Irhuma
doaj   +1 more source

Combination of Two Rapid Ophthalmic Test Kits for Improved Diagnosis in Cases of Severe Binocular Conjunctivitis

Diagnostics, 2020
Introduction: Diagnosis of conjunctivitis can be sometimes difficult, especially in cases of severe conjunctivitis and those involving both eyes. In this study, we performed commercial tests for adenovirus (Capilia Adeno Eye®) and total tear IgE ...
Asako Kodama, Fumitaka Kobayashi, Hao Yung Yang, Kazumi Fukagawa, Hiroyuki Yazu, Hiroshi Fujishima   +5 more
doaj   +1 more source

Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well‐Tolerated in a Pivotal Phase III Trial

Allergy, EarlyView.
A pivotal Phase III DBPC adaptive trial was conducted with PQ Grass 27600 SU. The primary endpoint EAACI‐CSMS0–6 demonstrated a highly significant, clinically meaningful improvement for PQ Grass of −0.27 points (95% CI: −0.42 to −0.12), corresponding to a relative difference of −20.3% (p = 0.0005) over placebo. Highly consistent secondary endpoints and
Stefan Zielen, Jonathan A. Bernstein, Gunter J. Sturm, Marek Jutel, Oliver Pfaar, the RESONATE Investigator Group, R. Gattringer, K. Gangl, J. Potesil, T. Sykora, M. Mattauchova, P. Panzner, M. Kasl, Z. Chovancova, T. Hofstetr, J. Poloniova, A. Zlamal, J. Haas, F. Heimlich, C. Korte, S. Ballenberger, J. Grosskopf, P. Heymer, C. Bergmann, M. Froer, G. Hoheisel, U. Thieme, C. Grigat, U. Schaefer, P. El Naib, A. Schwinn, S. Runge, M. Worm, S. Pauser, M. Jandl, J.‐C. Bohn, C. von Engelhardt, A. Schaefer, J. Rieker‐Schwienbacher, M. Cuevas, S. Lassmann, Y. Yarin, T. Nyeky, I. Szanyi, V. Urban, J. Nemes, P. Borowy, Z. Siergiejko, E. Janusik, B. Tluczykont, D. Madra‐Rogacka, S. Ptaczek, I. Wojciechowska, J. Orlicz‐Widawska, M. Żurowska‐Gębala, T. Hofman, S. Tokarski, M. Bederska, A. Latos, K. Kowal, E. Markut‐Miotla, E. Pisarczyk‐Bogacka, P. Kuna, B. Majorek‐Olechowska, A. Chmielewska, B. Kucinska, C. Chwala, P. Parikh, J. Sublett, J. Weiss, J. Leflein, P. Shapero, D. McNeil, K. O’Brien, E. Sher, G. Steven, L. Ford, A. Darter, L. Clore, D. Elkayam, G. Myers, J. Matz, M. Vanderwalker, S. Smiley, J. DeAngelo, A. Montanaro, J. Delgado, W. Greisner, C. Thornblade, M. Moss, Mohamed H. Shamji, Ralph Mösges, Markus Berger, Uwe E. Berger, Lawrence DuBuske, Janice A. Layhadi, Ludger Klimek, Markus Ollert, Murray A. Skinner, Matthias F. Kramer, Pieter‐Jan de Kam   +100 more
wiley   +1 more source

Development of a Conjunctivitis Outpatient Rate Prediction Model Incorporating Ambient Ozone and Meteorological Factors in South Korea

Frontiers in Pharmacology, 2018
Ozone (O3) is a commonly known air pollutant that causes adverse health effects. This study developed a multi-level prediction model for conjunctivitis in outpatients due to exposure to O3 by using 3 years of ambient O3 data, meteorological data, and ...
Jeong-Won Seo, Jong-Sang Youn, SeJoon Park, Choun-Ki Joo   +3 more
doaj   +1 more source

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion

Journal of the European Academy of Dermatology and Venereology, 2019
Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab.
J. Thyssen, J. Thyssen, M. Bruin-Weller, A. Paller, Y. Leshem, Christian Vestergaard, M. Deleuran, Aaron M Drucker, Aaron M Drucker, Regina Foelster-Holst, C. Traidl‐Hoffmann, C. Traidl‐Hoffmann, K. Eyerich, Alain Taïeb, John Su, John Su, T. Bieber, T. Bieber, M. Cork, L. Eichenfield, E. Guttman‐Yassky, A. Wollenberg   +21 more
semanticscholar   +1 more source

The Role of IgE in Crohn's Disease by Impairing the Capacity of Plasmacytoid Dendritic Cells to Generate FOXP3+ Tregs

Allergy, EarlyView.
We uncover an unprecedented role for IgE in CD. CD patients, regardless of allergic status and similar to allergic patients, display higher levels of circulating IgE+ and FcεRI+ immune cells, including pDCs, which are concomitant to fewer Tregs. In vitro experiments show that the anti‐IgE monoclonal antibody omalizumab restores the ability of pDCs from
Andrés de la Rocha‐Muñoz, Cristina Benito‐Villalvilla, David Olivares, Sofía Sirvent, Miguel A. García‐Brenes, Alba Angelina, Leticia Martín‐Cruz, Javier Cuesta, Paolo Tassinari, Xavier Jaumont, Carlos Taxonera, Oscar Palomares   +11 more
wiley   +1 more source

Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis

JAMA dermatology, 2018
Importance Clinical trials of dupilumab for atopic dermatitis (AD) have reported an increased incidence of conjunctivitis in patients who received dupilumab compared with those who received placebo.
Alison D Treister, Cheryl Kraff-Cooper, P. Lio   +2 more
semanticscholar   +1 more source